MedImmune, its parent company AstraZeneca and a handful of other pharma companies and health groups announced a broad lung cancer trial on Monday, looking to use patients' genomic profiles to match them with therapies.
The Lung Cancer Master Protocol, or Lung-MAP, trial will explore five product candidates as treatments for advanced squamous cell lung cancer. That includes MedImmune's MEDI4736, according to spokeswoman Tracy Rossin.